
Most-Favoured Nation Drug Pricing Risks Transatlantic Rift
When the Trump administration signed its Most-Favoured Nation (MFN) executive order in 2025, few doubted the measure would shake global pharmaceutical markets. By tying U.S. drug prices to the lowest government-negotiated rates in Europe and Canada, the White House pitched the plan as relief for American patients at the pharmacy counter.